219 related articles for article (PubMed ID: 7509485)
1. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
2. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
4. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Kraljić I; Kovacić K; Tarle M
Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
7. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
10. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Dürer A; Theyer U; Haberl I; Ulsperger E; Baumgartner G; Hamilton G
Prostate; 1999 Oct; 41(2):71-7. PubMed ID: 10477903
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
[TBL] [Abstract][Full Text] [Related]
13. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
Tarle M; Radoś N
Prostate; 1991; 19(1):23-33. PubMed ID: 1715080
[TBL] [Abstract][Full Text] [Related]
14. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
15. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
[TBL] [Abstract][Full Text] [Related]
16. Serum markers for monitoring of prostatic carcinoma.
Polito M; Minardi D; Recchioni A; Giannulis I; De Sio G; Muzzonigro G
Prostate; 1997 Nov; 33(3):208-16. PubMed ID: 9365550
[TBL] [Abstract][Full Text] [Related]
17. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor.
Frković-Grazio S; Kraljić I; Trnski D; Tarle M
Anticancer Res; 1994; 14(5B):2151-6. PubMed ID: 7840515
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]